Would you consider PARP inhibition in a patient with metastatic prostate cancer and a germline BRCA2 variant of unknown significance?  

Or would you restrict such treatment to patients with known pathogenic germline BRCA mutations?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at University of Minnesota–Masonic Cancer Center
Short answer: I completely agree with Dr. @Andrew ...
Sign in or Register to read more